Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis-Reference-Cited by-同舟云学术

Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis

Published:2016-09-01 Issue:5 Volume:48 Page:1503-1507
ISSN:0903-1936
Container-title:European Respiratory Journal
language:en
Short-container-title:Eur Respir J

Author:

Sotgiu Giovanni,Tiberi Simon,D'Ambrosio Lia,Centis Rosella,Alffenaar Jan Willem,Caminero Jose A.,Abdo Arbex Marcos,Alarcon Guizado Valentina,Aleksa Alena,Dore Simone,Gaga Mina,Gualano Gina,Kunst Heinke,Payen Marie-Christine,Roby Arias Aurora Jazmín,Skrahina Alena,Solovic Ivan,Sulis Giorgia^ORCID,Tadolini Marina,Zumla Alimuddin,Migliori Giovanni Battista^ORCID

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Reference15 articles.

1. World Health Organization. Global Tuberculosis Report 2015. WHO/HTM/TB/2015.22. Geneva, World Health Organization, 2015.

2. Multidrug-resistant tuberculosis around the world: what progress has been made?

3. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis

4. Classification of antituberculosis drugs: a new proposal based on the most recent evidence

5. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update WHO/HTM/TB/2016.04. Geneva, World Health Organization, 2016.

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study;The Lancet Infectious Diseases;2024-06

2. Comparison of short term and long term multidrug resistant tuberculosis treatment outcomes in tertiary care settings;Journal of King Saud University - Science;2024-04

3. Operational research as a mechanism to improve treatment outcomes for drug-resistant TB in the WHO European Region;IJTLD OPEN;2024-03-01

4. A systematic review of the costs of diagnosis for multidrug-resistant/extensively drug-resistant TB in different settings;The International Journal of Tuberculosis and Lung Disease;2023-05-01

5. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial;Trials;2021-09-25